Which stocks are the Street’s very best analysts recommending right now? We turned to the popular Daily Analyst Ratings tool to pinpoint stock recommendations from the Top 25 Analysts on TipRanks. These analysts are the best out of over 4,700 tracked analysts. They regularly crush the market with their accurate stock ratings and analysis.
To find these 5 top stocks, we set the filters to only show the latest ratings from five-star analysts. Scanning the results quickly reveals the most compelling investing opportunities. Note that in the screenshots below, the percentage in the circle is the analyst’s success rate and the second is their average return on a 1-year basis. If you click on the screenshot you can find further in-depth coverage of the stock including the overall Street consensus.
Now let’s take a closer look:
Bioverativ Inc (NASDAQ:BIVV)
Five-star analyst, Cowen & Co’s Eric Schmidt, reiterated his buy rating on Bioverativ Inc two days ago. BIVV is a biopharma that specializes in rare blood diseases such as hemophilia. Schmidt’s buy rating comes with a bullish $80 price target- the stock’s highest price target so far. Given that BIVV is currently trading at just $56, this suggests big upside potential of 43%.
The company has just reported very strong results for the third quarter, driven by strong Eloctate sales (+41% Y/Y). Following the report, Schmidt explains his reasoning on the stock. “We view BIVV’s hemophilia franchise as fairly durable and are excited about BIVV009’s $1.5B+ potential in CAD [coronary artery disease].” He expects the company to beat existing guidance of 23-25% Y/Y revenue growth “by a meaningful margin”.
MuleSoft Inc (NYSE:MULE)
Two days ago, one of the best analysts on TipRanks assigned a buy rating to MuleSoft Inc. Canaccord Genuity’s Richard Davis gave the stock a bullish $30 price target (the stock is currently trading at $24). MuleSoft, a software company that provides integration software for connecting applications, data and devices, only went public back in February. The stock rose over 45% on the first day of trading, making investors nervous.
Leave A Comment